Skip to main content
BIIB
NASDAQ Life Sciences

Biogen to Acquire RayThera for Up to $1 Billion, Bolstering Immunology Pipeline

Reported by Reuters
Sentiment info
Positive
Importance info
8
Price
$199.58
Mkt Cap
$29.331B
52W Low
$121.05
52W High
$205.97
Market data snapshot near publication time

Summary

Biogen announced an agreement to acquire private biotechnology company RayThera for up to $1 billion. This strategic move aims to expand Biogen's pipeline in immunology. This follows the company's recent completion of the $5.3 billion Apellis Pharmaceuticals acquisition in May, indicating continued focus on M&A for pipeline growth. The $1 billion investment is a material commitment to its immunology franchise.

At the time of this announcement, BIIB was trading at $199.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3B. The 52-week trading range was $121.05 to $205.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.

Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Jun 18, 2026, 5:52 AM EDT
Source: Reuters
Importance Score:
8
Biogen to Acquire RayThera for Up to $1 Billion, Bolstering Immunology Pipeline
Price at Filing: $199.58
Real-time Price: $199.58 info
Change: $0 (0%) info
Market Cap: $29.331B info
Sentiment: Positive
View Wiseek Article
BIIB
Jun 17, 2026, 6:59 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Biogen Acquires RayThera to Boost Immunology Pipeline
Price at Filing: $197.92
Real-time Price: $199.58 info
Change: +$1.66 (+0.84%) info
Market Cap: $29.331B info
Sentiment: Positive
View Wiseek Article
BIIB
Jun 16, 2026, 9:28 AM EDT
Source: Reuters
Importance Score:
7
Biogen Canada Fails to Secure Reimbursement Deal for Skyclarys
Price at Filing: $197.77
Real-time Price: $199.58 info
Change: +$1.81 (+0.92%) info
Market Cap: $29.331B info
Sentiment: Negative
View Wiseek Article
BIIB
Jun 10, 2026, 4:49 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Biogen Reclassifies Apellis Acquisition as Non-Significant, Removes Pro Forma Financial Requirement
Price at Filing: $194.24
Real-time Price: $199.58 info
Change: +$5.34 (+3%) info
Market Cap: $29.331B info
Sentiment: Neutral
View Wiseek Article
BIIB
Jun 04, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
FDA Grants Breakthrough Therapy Designation to Biogen's Salanersen for Spinal Muscular Atrophy
Price at Filing: $195.96
Real-time Price: $199.58 info
Change: +$3.62 (+2%) info
Market Cap: $29.331B info
Sentiment: Positive
View Wiseek Article
BIIB
Jun 01, 2026, 1:06 AM EDT
Source: Reuters
Importance Score:
9
Biogen's DZP Drug Hits Phase 3 Success for Lupus, Boosting Pipeline
Price at Filing: $196.00
Real-time Price: $199.58 info
Change: +$3.58 (+2%) info
Market Cap: $29.331B info
Sentiment: Positive
View Wiseek Article
BIIB
May 27, 2026, 2:23 AM EDT
Source: Reuters
Importance Score:
8
Italy Opens Antitrust Probe into Biogen Over Alleged Dominance in MS Drug Market
Price at Filing: $193.08
Real-time Price: $199.58 info
Change: +$6.50 (+3%) info
Market Cap: $29.331B info
Sentiment: Negative
View Wiseek Article
BIIB
May 21, 2026, 6:36 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Biogen, Denali Parkinson's Drug Fails Phase 2b Trial, Development Halted
Price at Filing: $187.50
Real-time Price: $199.58 info
Change: +$12.08 (+6%) info
Market Cap: $29.331B info
Sentiment: Negative
View Wiseek Article
BIIB
May 14, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
9
Biogen Completes $5.3 Billion Acquisition of Apellis Pharmaceuticals, Secures $2 Billion Term Loan
Price at Filing: $213.49
Real-time Price: $199.58 info
Change: -$13.91 (-7%) info
Market Cap: $29.331B info
Sentiment: Positive
View Wiseek Article
BIIB
May 14, 2026, 7:20 AM EDT
Source: Reuters
Importance Score:
8
Biogen to Advance Alzheimer's Drug Diranersen to Late-Stage Despite Phase 2 Miss
Price at Filing: $223.99
Real-time Price: $199.58 info
Change: -$24.41 (-11%) info
Market Cap: $29.331B info
Sentiment: Positive
View Wiseek Article